A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer
- Authors
- Ahn, Hee Kyung; Jung, Minkyu; Sym, Sun Jin; Shin, Dong Bok; Kang, Shin Myung; Kyung, Sun Young; Park, Jeong-Woong; Jeong, Sung Hwan; Cho, Eun Kyung
- Issue Date
- Aug-2014
- Publisher
- SPRINGER
- Keywords
- Non-small cell lung cancer; Gemcitabine; Paclitaxel; Chemotherapy; Genexol-PM
- Citation
- CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.74, no.2, pp.277 - 282
- Journal Title
- CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Volume
- 74
- Number
- 2
- Start Page
- 277
- End Page
- 282
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12444
- DOI
- 10.1007/s00280-014-2498-5
- ISSN
- 0344-5704
- Abstract
- Genexol-PM is a Cremorphor EL (CrEL)-free polymeric micelle formulation of paclitaxel that allows higher-dose administration with less hypersensitivity. This study was designed to evaluate the efficacy and safety of Genexol-PM and gemcitabine combination in advanced non-small cell lung cancer patients as a first-line treatment. This is a prospective, single-arm, single-center phase II study. Patients with advanced NSCLC received Genexol-PM at 230 mg/m(2) on day 1 and gemcitabine 1,000 mg/m(2) on day 1 and day 8 of a 3-week cycle. Six cycles of chemotherapy were planned unless there was disease progression. The primary endpoint was overall response rate. Forty-three patients received the study drugs with a median of 4 cycles per patient (range 1-6). The overall response rate was 46.5 %. The median progression-free survival was 4.0 months (95 % CI 2.0-6.0 months), and median overall survival was 14.8 months (95 % CI 9.1-20.5 months). The most common toxicities were anemia (n = 29, 67 %), asthenia (n = 17, 40 %), myalgia (n = 16, 37 %), peripheral neuropathy (n = 15, 35 %), and diarrhea (n = 12, 30 %). The most common grade 3/4 adverse events were neutropenia (n = 7, 16 %) and pneumonia (n = 5, 12 %). Two patients died of pneumonia and dyspnea. CrEL-free paclitaxel in combination with gemcitabine demonstrated favorable antitumor activity with little emetogenicities in non-small cell lung cancer patients. However, frequent grade 3/4 toxicities were observed, and safety should be evaluated thoroughly in future studies.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12444)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.